Concord Imaging Center News & Links
New 3D Mammography at Concord Imaging offers better chance to diagnose
breast cancer earlier, at more treatable stages
Concord Imaging is excited to offer
3D mammography (breast tomosynthesis) for breast cancer screening. Breast tomosynthesis produces a three-dimensional view of the breast
tissue that helps radiologists identify and characterize individual breast
structures without the confusion of overlapping tissue.
The center’s Selenia® Dimensions® breast tomosynthesis system
is made by Hologic, a world leader in digital mammography. The Selenia
Dimensions system offers exceptionally sharp breast images, an advanced
ergonomic design providing more patient comfort, and the ground-breaking
tomosynthesis platform designed to deliver superior screening and diagnostic
performance for all breast types. 1
We believe breast tomosynthesis will benefit all screening and diagnostic
mammography patients, and is especially valuable for women receiving a
baseline screening, those who have dense breast tissue and/or women with
a personal history of breast cancer.
Breast cancer screening with tomosynthesis when combined with a conventional
2D mammography has a 40% higher invasive cancer detection rate than conventional
2D mammography alone.2-4 Tomosynthesis technology gives radiologists increased
confidence with up to a 40% reduction in recall rates. 4-5
The tomosynthesis screening experience is similar to a traditional mammogram.
During a tomosynthesis exam, multiple, low-dose images of the breast are
acquired at different angles. These images are then used to produce a
series of one-millimeter thick slices that can be viewed as a 3D reconstruction
of the breast.
By offering women the latest and more accurate6 technology in mammography,
Concord Imaging expects to increase the number of area women who will
be routinely screened. Breast cancer is the second leading cause of cancer
death among women, exceeded only by lung cancer. Statistics indicate that
one in eight women will develop breast cancer sometime in her lifetime.
The stage at which breast cancer is detected influences a woman’s
chance of survival. If detected early, the five-year survival rate is
98 percent. 7
Concord Imaging is committed to the fight against breast cancer. In offering
breast tomosynthesis digital mammography, Concord Imaging provides the
latest in imaging technology. Tomosynthesis (3D Mammography) is now available
at Concord Imaging. If you would like to schedule a mammogram or have
questions about this important breast health procedure, please contact
Scheduling at 210-572-2222.
1 Rafferty E, Park J, Philpotts L, et al. “Assessing Radiologist
Performance Using Combined Digital Mammography and Breast Tomosynthesis
Compared with Digital Mammography Alone: Results of a Multicenter, Multireader
Trial.” Radiology. 2013 Jan; 266(1):104-13. Epub 2012 Nov 20.
2 Skaane P, Bandos A, Gullien R, et al. “Comparison of Digital Mammography
Alone and Digital Mammography Plus Tomosynthesis in a Population-based
Screening Program.” Radiology. 2013 Apr; 267(1):47-56. Epub 2013 Jan 7.
3 Ciatto S, Houssami N, Bernardi D, et al. “Integration of 3D Digital
Mammography with Tomosynthesis for Population Breast-Cancer Screening
(STORM): A Prospective Comparison Study”
The Lancet Oncology. 2013 Jun;14(7):583-589. Epub 2013 Apr 25.
4 Rose S, Tidwell A, Bujnock L, et al. “Implementation of Breast
Tomosynthesis in a Routine Screening Practice: An Observational Study.”
American Journal of Roentengenology. 2013 Jun; 200(6): 1401-1408. Epub
2013 May 22.
5 Haas B, Kalra V, Geisel, J et al. “Comparison of Tomosynthesis
Plus Digital Mammography and Digital Mammography Alone for Breast Cancer
Radiology. 2013 Jul 30. [Epub ahead of print].
6Zuley M, Bandos A, Ganott M, et al. “Digital Breast Tomosynthesis
versus Supplemental Diagnostic Mammographic Views for Evaluation of Noncalcified
Breast Lesions.” Radiology. 2013 Jan; 266(1):89-95. Epub 2012 Nov 9.
7 Breast Cancer Facts & Figures 2011, American Cancer Society.
3D Mammography Videos
Amyvid for Alzheimer’s Offered
Amyvid (Florbetapir F 18 Injection) is a newly FDA-approved agent used
to estimate the amount of amyloid plaque in the brain of patients with
decline in mental function who are being evaluated for the diagnosis of
Alzheimer's disease. After injection of Amyvid, a PET scan of the
brain is obtained which demonstrates areas where beta amyloid plaque,
which is associated with Alzheimer's disease, is deposited. This can
be helpful to physicians in either excluding or making the diagnosis of
Alheimer's dementia. Unfortunately, at this time , no insurances cover
payment for this exam so it is only performed on a cash basis at the time
Digital Wireless Xray Unit in Texas!
Concord Imaging is pleased to announce the installation of the Carestream
DRX-1 System at their Creekside location for performing Digital Radiography.
Most current radiology facilities use Computed Radiography (CR) for performing
radiographs (traditional “X-rays”). CR replaced the old system
of Xray film in cassettes that had to be run through a processor. The
CR systems still have to use a laser light to “read” the xray
image on a cassette and this takes about 60 seconds per image.
Concord Imaging at Creekside has added the latest in state of the art technology
to their Xray capabilities. With the new Carestream DRX-1 system, an all-digital
detector plate is placed behind the area to be imaged and the xray exposure
is taken in the conventional manner. From this point forward, the information
is transmitted digitally in just a few seconds from the digital detector
to the console and the image is ready to be sent to the PACS system where
it is stored and can be interpreted by the radiologist. The image is transmitted
and the technologist is ready to position the patient for the next exposure
in a matter of seconds rather than minutes.
From a patient and referring office perspective, this allows Concord Imaging
at Creekside to perform Xray exams in much less time than any other facility.
This should translate into shorter exams for patients and less waiting
time to get into the exam room.
“We began to look at areas in our facility where we potentially experience
backlogs and Xray and Ultrasound were identified as areas where we sometimes
had patients waiting longer than desirable or difficulty scheduling,”
said Concord Imaging founder and radiologist Jeremy Wiersig, M.D. (Please
see Ultrasound News). “We pride ourselves on our service and taking
good care of patients, so when we learned about the DRX-1 Wireless DR
system, we started investigating it, “ We thought we could make
a real difference in patient wait and exam times and it’s really
proving to be true. And the image quality is really spectacular.”
Come experience the 1st wireless Digital Radiography system in Texas at
Concord Imaging the next time you need “Xrays”.
American Cancer Society Announces New Recommendations for MRI in Breast
Cancer - New Guidelines for MRI screening for breast cancer in high risk women.
Local staging of breast cancer: In patients with biopsy- proven malignancy, breast MRI is used to determine
extent of disease (multifocality and multicentricity) in the ipsi-lateral
breast and to screen for disease in the asymptomatic contra-lateral breast.
Neoadjuvant chemotherapy: MRI is used before and during the course of chemotherapy to evaluate chemotherapeutic
response and extent of residual disease prior to surgical treatment.
Post-lumpectomy bed evaluation/scar vs. recurrence: MRI is applied in patients with prior lumpectomy and questionable recurrence
within the lumpectomy bed on mammography and ultrasound.
Positive margins post lumpectomy: MRI is used to assess the extent of residual disease in patients with close
or positive margins post-lumpectomy. MRI can help determine if re-excision
or mastectomy will be necessary.
Chest wall invasion: MRI is indicated for the evaluation of chest wall involvement prior to
lumpectomy or mastectomy.
Occult primary: In patients presenting with axillary lymphadenopathy and no mammographic
evidence of malignancy, MRI is utilized to assess for an occult primary.
Palpable lump: In patients with a palpable lump and a negative diagnostic evaluation
on mammography and sonography, MRI may be useful to exclude an underlying
Problem-solving/difficult mammogram: MRI may be used as a problem-solving tool in the situation of a difficult
Screening of high-risk patients: Screening MRI is now recommended by the ACS for women with an approximate
20 percent to 25 percent or greater lifetime risk of breast cancer, including
women with a strong family history of breast or ovarian cancer and women
treated for Hodgkin's disease.
Implant integrity: Non-contrasted MRI using silicone-sensitive sequences is used to assess
implant integrity (intra- and extra-capsular implant rupture).
Alzheimer's Disease and PET Scans
Charlton Heston Speaks Out
Charlton Heston knows first hand that detecting Alzheimer's Disease
early gives patients extended quality time with loved ones. Heston announced
in 2002 that he had been diagnosed with Alzheimer's after a PET scan
detected signs of the disease.
UCLA researchers have found that PET scans enable physicians to diagnose
Alzheimer's before the symptoms set in, which gives patients options
to help delay the progression of the disease.
Using PET to determine if patients have Alzheimer's would correspond
to a 65% decrease in avoidable months of nursing home care, and a 48%
drop in unnecessary drug treatment, according to Dr. Daniel Silverman,
assistant professor of molecular and medical pharmacology and associate
director of imaging for the UCLA Alzheimer's Disease Center.
"Even a 6-month difference in the date of detection can profoundly
affect the progression of Alzheimer's," said Dr. Michael E. Phelps,
chair of the Department of Molecular Medical Pharmacology at the David
Geffen School of Medicine at UCLA.
PET scans offer Alzheimer's patients HOPE.
- Charlton Heston advocates the benefits of PET for early Alzheimer's
Detection (public service announcement from the Academy of Molecular Imaging):
- Medicare approves PET in Alzheimer's disease. The Centers for Medicare
and Medicaid Services (CMS) announced September 15, 2004 that it will
provide limited coverage for the use of FDG-PET in the diagnosis and treatment
of mild cognitive impairment (MCI) and early dementia in elderly patients
meeting certain criteria: >>More
Alzheimer's Foundation of America Supports Medicare Reimbursement for Brain Scans.
Press Release announcing the organization's support of the federal
government's proposal to provide Medicare reimbursement of PET for
some individuals with suspected Alzheimer's disease.
Made in Her Mother's Image? article from USAToday.com: "Experimental Brain scans may show Alzheimer's
in her future, or not."
Helpful Radiology Links